KP415 Classroom Study in Children (6-12 Years of Age) With ADHD

The study will consist of a Screening Period, an Open-Label Dose Optimization Phase, a
Double-Blind Treatment Phase and a Follow-Up Visit, as follows:

- Screening Period: Subjects will undergo a screening period up to 49 days prior to
entering into the Open-Label Dose Optimization Phase.

- Open-Label Dose Optimization Phase: During the Dose Optimization Phase, subjects will be
titrated to doses of 20, 30 or 40 mg KP415 based on tolerability and best individual
dose-response in the opinion of the Investigator.

- Double-Blind Treatment Phase: Eligible subjects will be randomized to receive single
daily doses of KP415 or Placebo for 7 days according to a randomization schedule. The
dose of KP415 given in the Treatment Phase will be the same as the optimized dose of
KP415 at the end of the Dose Optimization Phase. All subjects will receive their
assigned treatment daily for 7 days. The dose will be the same at each day of the
Treatment Period. Efficacy and safety assessments will be performed after the last dose
of the Treatment Period.

- Follow-Up Visit: 3 ±2 days after administration of the last dose of the Treatment Phase,
subjects will enter a Follow-Up Visit to evaluate safety parameters.

Inclusion Criteria:

1. Subject must meet Diagnostic and Statistical Manual of Mental Disorders - Fifth
Edition (DSM-5) criteria for a primary diagnosis of ADHD (combined, inattentive, or
hyperactive/impulsive presentation) per clinical evaluation and confirmed by the Mini
International Neuropsychiatric Interview for Children and Adolescents (MINI-KID).

2. Subject must have a score of at least 3 (mildly ill) on the clinician-administered
Clinical Global Impressions-Severity (CGI-S) scale.

3. Subject, subject's parent/legal guardian and caregiver (if applicable) must understand
and be willing and able to comply with all study procedures and visit schedule.

Exclusion Criteria:

1. Subject with any clinically significant chronic medical condition that may interfere
with the participant's ability to participate in the study.

2. Subject has any diagnosis of bipolar I or II disorder, major depressive disorder,
conduct disorder, obsessive-compulsive disorder, any history of psychosis, autism
spectrum disorder, disruptive mood dysregulation disorder (DMDD), intellectual
disability, Tourette's Syndrome, confirmed genetic disorder with cognitive and/or
behavioral disturbances.

3. Subject has evidence of any chronic disease of the central nervous system (CNS) such
as tumors, inflammation, seizure disorder, vascular disorder, potential CNS related
disorders that might occur in childhood, or history of persistent neurological
symptoms attributable to serious head injury.

4. Subject has a current (last month) psychiatric diagnosis other than specific phobia,
motor skills disorders, oppositional defiant disorder, sleep disorders, elimination
disorders, adjustment disorders, learning disorders, or communication disorders.
Participants with school phobia or separation anxiety will not be eligible.

5. Subject has any history of attempted suicide or clinically significant suicidal
ideation or subject has a C-SSRS score for suicidal ideation ≥2.

6. Subject has any clinically significant unstable medical abnormality, chronic disease,
or a history of a clinically significant abnormality of the cardiovascular,
gastrointestinal, respiratory, hepatic, or renal systems, or a disorder or history of
a condition that may interfere with drug absorption, distribution, metabolism, or
excretion of study drug.

7. Subject has a history or presence of abnormal ECGs.